DOYLESTOWN, PA (November 9, 2005) The Quigley Corporation (NASDAQ: QGLY),
announced today that on November 7th. 2005, its wholly owned subsidiary Quigley
Pharma received four additional Investigational New Animal Drug (INAD) numbers,
from the Center for Veterinary Medicine of the Food and Drug Administration.
The company's naturally derived QR-441A can now be tested upon dogs, cats,
horses and companion birds. The formula has previously been tested in a
combination of ten efficacious in-vitro and in-vivo studies (in-vivo studies
were conducted on ferrets), under the direction of Professor John Oxford, Dr.
Rob Lambkin and Sebastien Bossuyt at Retroscreen Virology, Queen Mary's School
of Medicine & Dentistry, University of London, UK.
Dr. Richard Rosenbloom, Quigley Pharma's Chief Operations Officer stated:
"Prompted by the new data upon the H3N8 Equine (horse) flu's cross over to
dogs, we can not only test QR-441A upon chickens, turkeys and ducks but have
received permission from the FDA to test upon companion animals: horses, dogs,
cats and birds. We believe that the mechanism of action of this all-natural
compound may prevent transmission within species as well as to other species.
Pets, especially dogs, have the most intimate contact with humans on a daily
basis. In addition to our concerns for our pet's health, the potential for
human infection has to be considered."
Quigley Pharma will be coordinating various protocols with the Center for
Veterinary Medicine to obtain the guidance for the best route to a drug license
for its potential drug. These studies shall be conducted in Biosafety Level 3
facilities across the United States and perhaps overseas.
The Quigley Corporation is the leading developer and marketer of diversified
health products. The company's proven success in launching first-in-category
health solutions supports the Pharma subsidiary in its efforts to develop
strong pharmaceutical compounds targeting diverse conditions such as diabetes
and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug
Administration or any other regulatory agency will grant an IND for human study
or take any other action to allow the aforementioned compound to be marketed.
Furthermore, no claim is made that the potential medicine discussed here is
safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a
diversified natural health medical science company. Its Cold Remedy segment is
a leading marketer and manufacturer of the COLD-EEZE® family of lozenges,
gums and sugar free tablets clinically proven to cut the common cold nearly in
half. COLD-EEZE customers include leading national wholesalers and
distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies. The Quigley Corporation has four (4) wholly owned
subsidiaries. Darius International markets health and wellness products through
its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc.
consists of two FDA approved facilities to manufacture COLD-EEZE® lozenges
as well as fulfill other contract manufacturing opportunities. Quigley Pharma
Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived
prescription drugs.
Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other factors
that may cause the company's actual performance or achievements to be
materially different from the results, performance or achievements expressed or
implied by the forward-looking statement. Factors that impact such
forward-looking statements include, among others, changes in worldwide general
economic conditions, changes in interest rates, government regulations, and
worldwide competition.
